If Sponsors Don’t Ask, FDA Can’t Always Deliver: Merck’s Suvorexant Dosing Debacle
Executive Summary
Sponsors may need to be more proactive in reaching out to the agency if they want to avoid the kind of dosing confusion currently facing Merck’s insomnia drug suvorexant, FDA indicates.